Real-world evidence of 18 F-fluciclovine Positron emission tomography/computed tomography performance for recurrent prostate cancer in the Veterans Affairs Health System.
Nadine A FriedrichLin GuJustin WallerAmanda M De HoedtZachary KlaassenStephen J FreedlandPublished in: The Prostate (2024)
F-fluciclovine PET/CT performance in an equal access health care system confirms higher detection rates than traditional imaging methods, but positivity is highly influenced by PSA at time of imaging. Additionally, patients currently receiving ADT have at least four times higher likelihood of a positive scan, showing that scan positivity isn't negatively affected by ADT status in this study. Finally, White men were more likely to have a positive scan, the reasons for which should be explored in future studies.
Keyphrases
- positron emission tomography
- pet ct
- computed tomography
- prostate cancer
- high resolution
- magnetic resonance imaging
- end stage renal disease
- radical prostatectomy
- dual energy
- ejection fraction
- newly diagnosed
- pet imaging
- chronic kidney disease
- contrast enhanced
- peritoneal dialysis
- current status
- middle aged
- patient reported